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Abstract
Objective: To evaluate the positive predictive value (PPV) of group B Streptococcus (GBS)
cultures at 35–37 weeks of gestation relative to GBS colonization status at delivery.
Methods: Rectovaginal swabs from 221 women at labor in four Lisbon hospitals were collected
for GBS screening according to the CDC guidelines.
Results: The PPV was 24.4%. IAP was administered to 100% of prenatally GBS positive women.
There was no case of early onset GBS disease (EOD).
Conclusions: Poor accuracy of prenatal cultures in identifying true candidates for IAP highlights
the need for Portuguese clinical and laboratory guidelines to prevent EOD and antibiotic
overtreatment of pregnant women.
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Introduction
Streptococcus agalactiae, group B Streptococcus (GBS) has
multiple serotypes and is an opportunistic human pathogen
that can lead to life-threatening infections in newborns and
immunocompromized adults [1]. Maternal GBS carriage has
been recognized as the major risk factor of early onset disease
in newborns (EOD, 57 days of age) [1,2]. Up to 30% of
pregnant women are anogenital colonized, although the
carrier status is considered dynamic during pregnancy [2,3].
CDC guidelines [2,4] recommend GBS screening at 35–37
weeks of gestation in order to identify women at risk that
should undergo intrapartum antibiotic prophylaxis (IAP) to
avoid transmission to the newborn during labor; IAP became
responsible for the reduction of EOD in developed countries.
Nevertheless, strategies to prevent late onset disease (LOD),
which occurs after the first week of life, have yet to emerge,
as IAP is unable to avoid LOD. The screening-based approach
is challenging, as its efficacy relies on its capacity to predict
GBS colonization status at the time of labor. Published
reports [5,6] showed that both negative (NPV) and positive
(PPV) predictive values of prenatal GBS cultures relatively
to the GBS status at delivery are suboptimal, especially the
PPV. We aimed to evaluate the PPV of GBS positive culture
at 35–37 weeks of gestation considering the GBS colonization
status at delivery.
Methods
Patients and study design
Between March 2008 through June 2009, 221 pregnant
women presenting a positive result for GBS at 35–37 weeks
of gestation from 4 hospitals (Dona Estefaˆnia Hospital, n¼ 9;
Maternity Alfredo da Costa, n¼ 42; Fernando Fonseca
Hospital, n¼ 67; and CUF Descobertas Hospital, n¼ 103)
were selected for this study. It was not possible to determine
the laboratories (private and/or public) where pregnant
women performed their GBS prenatal nor the methodologies
that were used by those laboratories. The unknown coloniza-
tion status at delivery was also used as an inclusion criterion
in order to verify the intrapartum positivity of GBS in this
group of women (n¼ 88). Considering the main focus of this
study, and due to budget constraints, women with negative
GBS cultures at 35–37 weeks of gestation were excluded.
All pregnant delivering before 35 weeks of gestation as
well as pregnant that had received antibiotic treatment up to
3 weeks before admission were excluded.
This study was approved by the ethics board of the involved
institutions, and a written informed consent was obtained from
all women prior to their enrolment in the study. Information
about age, obstetric risk factors, and type of delivery were
collected. Later, information on whether newborns developed
EOD during the hospital stay was also acquired.
Collection and culture of specimens
A combined recto-vaginal swab was collected from each
parturient on admission for delivery. Swabs were then
maintained in a non-nutritive Amies medium (Biome´rieux)
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at room temperature until processing at the National Institute
of Health in Lisbon, within 24 h, according to the described
by the CDC guidelines [4]. Briefly, each swab was inoculated
in Todd Hewitt selective media broth at 37C, 5% CO2 for
18 h and sub-cultured on Columbia agar supplemented
with 5% sheep blood (COS) (Biome´rieux) at 37C in 5%
CO2 for an additional period of 24–48 h.
GBS identification and antibiotic susceptibility testing
S. agalactiae isolates were identified by standard criteria
on the basis of colony morphology, Gram staining, non-
hydrolysis of aesculin on bile-aesculin agar and group B
latex-agglutination test. Antimicrobial susceptibility testing
(penicillin G, erythromycin, clindamycin and vancomycin)
was performed by Etest according to the Clinical and
Laboratory Standards Institute guidelines [7].
Capsular typing and screening of ST-17
hypervirulent lineage
Capsular typing was performed by using specific antisera
for serotypes Ia to V (Essum AB) and cps genotyping [3].
The detection of ST-17 lineage was achieved by PCR, as
described elsewhere [8].
Statistics
Positive predictive value (PPV) of prenatal GBS cultures
was calculated through the following formula: [(Number of
women GBSþ/þ)7 (number of women GBSþ/þ and
GBSþ/)] 100%, where GBSþ/þ and GBSþ/ correspond
to intrapartum positive and negative results, respectively
(all samples had been positive positive at prenatal stage) [5].
Results
Vaginal-rectal cultures were obtained from 221 GBS positive
women on admission for delivery, 118 (53.4%) and 103
(46.6%) from three public and one private hospitals, respect-
ively. Overall, the average maternal age was 30.4 years (range,
14–45 years) and the average gestational age at labor was 39.0
weeks (range, 35.9–41.4 weeks). The mode of delivery was
vaginal or cesarean in 166 (75.1%) and 55 (24.9%) women,
respectively. Among 55 women giving birth by cesarean
section, 38 (69.1%) were performed electively and 17 (30.9%)
were performed after labor, of whom 38 (69.1%) occurred at
the private hospital. Of 221 prenatally GBS-positive women,
only 54 remained positive at delivery, corresponding to a PPV
of 24.4%. All these 54 prenatal GBS-positive women received
IAP (ampicillin was the first choice for IAP in the four
hospitals). However, on a risk-based screening (e.g. preterm
delivery), only 11 (5%) would have justified antibiotic
treatment.
None of the 88 parturients without prior GBS screening
revealed intrapartum GBS colonization; however, 9/9 attend-
ing to the private hospital and 17/79 attending to public
hospitals (the ones presenting risk factors: preterm deliveries
[n¼ 14]; GBS bacteriuria during the current pregnancy
[n¼ 2]; previous child with EOD [n¼ 1]) received IAP.
The serotype distribution showed the predominance of
serotype III (25/54 [46.3%]) followed by serotypes Ia (10/54
[18.5%]), II (9/54 [16.7%]), V (7/54 [12.9%]), Ib (2/54
[3.7%]) and IV (1/54 [1.9%]), which was quite similar to that
described in Portugal for GBS colonization during the last
trimester of pregnancy [3]. The lineage ST17 was identified
in 56% (14/25) of the isolates belonging to serotype III;
however, no newborn developed EOD during hospital stay.
All clinical isolates were fully susceptible to penicillin G
or vancomycin. We observed a resistance rate of 7.4% to
erythromycin and 1.8% to clindamycin, which were low when
compared to our previous data [3].
Discussion
In the present study, public and private hospitals evidenced
differences regarding both the GBS screening during preg-
nancy and the selection of candidates for IAP. As an example,
only nine pregnant cases were presented to the private
hospital without GBS screening at 35–37 weeks of gestation,
and all received IAP, versus 79 attending to public hospitals,
where IAP was provided exclusively to the 17 parturients
comprehending risks. The lack of GBS screening during
pregnancy suggests unawareness, or indifference regarding
the free health care provided under the supervision of low-
risk pregnancy in Portugal. Thus, social factors contributing
to the exclusion from pregnancy surveillance in Portugal seem
to need urgent assessment and adjustment.
Although a great heterogeneity of PPVs has been described
[5,6,9] ranging (43–100%), our study revealed a considerably
low PPV of 24.4%. This weak concordance between prenatal
and intrapartum culture results could be attributed to several
variables, namely (1) timing of prenatal GBS screening;
(2) laboratory methodologies; and (3) antibiotic usage.
The influence of the timing of prenatal GBS screening
in this study would be neglectable; in fact, all enrolled GBS
positive women were screened at 35–37 weeks of gestation,
which has been considered ideal for correlating with GBS
colonization status at delivery, by longitudinal studies [9].
The observed discrepancy could be explained, in part,
by methodological heterogeneity (sampling, swab storage
and transport, and culturing procedures) that could not be
determined in the present study. In fact, in Portugal, the health
system allows pregnant women to freely choose the
laboratories where antenatal GBS screening is performed
(screening at the same hospital of delivery is rare),
implicating that a multitude of laboratories were involved,
each one using their particular GBS detection protocols.
There is neither Portuguese GBS laboratory screening guide-
lines nor recommendations for following scientific guidelines
internationally accepted, such as the provided by the CDC.
In this scenario, an heterogeneity of methodologies applied
to GBS detection are to be expected, comprehending the
proposed by the CDC guidelines but also less expensive and
time-consuming procedures, such as direct plating in both
Columbia 5% sheep blood agar and chromogenic medium
(such as Strepto B ID or Granada). Each procedure has
inherent limits and drawbacks that can lead to GBS
misidentification.
Another technical explanation could hold on the prolifer-
ation of non-GBS isolates during storage and transport,
such as Enterococcus and Proteus species, impairing the
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identification and recovery of GBS on blood agar plates.
Indeed, and consistent with published data [10], 12.2% of our
intrapartum cultures from prenatally GBS-positive women
evidenced an overgrowth of Gram negative bacteria in blood
agar plates (not supplemented with antibiotics), which might
have obscured GBS colonies culminating in false-negative
results. This emphasizes the need to improve the subculture
system by using selective GBS media (Columbia agar with
colistin and nalidixic acid or a commercial chromogenic
agar), as is currently recommended by the 2010 CDC
guidelines [2]. Indeed, Van Dyke and colleagues [11] revealed
that 61.4% of EOD cases occurred in term newborns whose
mothers were GBS-negative at 35–37 weeks. Whether those
negative cultures were false-negative results or the parturients
acquired GBS during the interval between pregnancy screen-
ing and delivery is unknown, but it surely evidences major
variations in GBS colonization status during pregnancy.
As we excluded pregnant subjected to antibiotic treatment
within 3 weeks before delivery, we would expect no influence
of this factor for the low PPV; however, we cannot exclude
that some pregnant women during their hospital admission
questionnaire omitted (by unidentified reasons) taking medi-
cation, namely antibiotics. In fact, although in Portugal
a medical prescription is required for antibiotic purchase,
irregularities to this rule exist, allowing self-medication.
In conclusion, the reasons underlying a low PPV of
prenatal culture in predicting GBS colonization during
labor in Portugal are hard to determine due to the lack of
national clinical and laboratory guidelines for GBS prevention
that would contribute to the uniformity and quality of GBS
screening. This requisite would surely contribute to a higher
PPV that would prevent EOD while avoiding overtreatment
of pregnant women.
Also, and until the availability of an effective GBS
vaccine, new reliable and fast intrapartum diagnostic tools
should be developed to supplement antenatal GBS screening.
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